argenx SE logo
argenx SE ARGX
$ 780.25 -0.98%

Annual report 2025
added 04-18-2026

report update icon

argenx SE EPS Ratio 2011-2026 | ARGX

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.

Calculated as:

EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio argenx SE

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - -7.99 -13.4 -4.69 - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-4.69 -13.4 -8.69

References

  1. Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer EPS Ratio Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-15.4 - 2.43 % $ 254 M germanyGermany
I-Mab I-Mab
IMAB
-7.66 - - $ 866 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-24.9 - - $ 1.01 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-31 - -18.52 % $ 27.3 M britainBritain
Aptorum Group Limited Aptorum Group Limited
APM
-0.19 $ 0.9 -2.33 % $ 6.62 M chinaChina
Biophytis SA Biophytis SA
BPTS
-0.26 - -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
1.51 - 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
1.37 $ 21.96 -0.68 % $ 3.64 B usaUSA
Advaxis Advaxis
ADXS
-7.99 - -9.65 % $ 45.9 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
-1.57 - 1.93 % $ 17.4 M usaUSA
Akouos Akouos
AKUS
-2.52 - 0.23 % $ 488 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
-2.45 $ 6.4 4.4 % $ 63.3 M usaUSA
Allakos Allakos
ALLK
-2.14 - - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
-2.85 - 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-10.7 - -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
2.1 $ 21.41 1.9 % $ 1 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
-3.25 - - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
-0.07 - 5.93 % $ 314 M canadaCanada
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
-1.11 - -2.5 % $ 5.88 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
-1.42 - - $ 8.42 M usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
-0.186 $ 12.26 3.72 % $ 1.62 B australiaAustralia
Aptinyx Aptinyx
APTX
-0.96 - -39.0 % $ 4.57 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
-1.91 - -10.17 % $ 12.2 K usaUSA
Aravive Aravive
ARAV
-2.1 - -13.39 % $ 1.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
-1.62 - 17.91 % $ 11.1 M usaUSA
BioNTech SE BioNTech SE
BNTX
42.2 $ 105.46 -0.09 % $ 27.2 B germanyGermany
Avenue Therapeutics Avenue Therapeutics
ATXI
-0.93 - -52.27 % $ 4.45 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-0.36 - - $ 26.5 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
-0.78 $ 4.08 0.25 % $ 436 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
-0.13 $ 23.26 1.75 % $ 2.96 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
-2.46 - - $ 7.46 M israelIsrael
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
-1.08 $ 1.44 -5.88 % $ 383 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
-10.4 - -45.71 % $ 1.2 M canadaCanada
AstraZeneca PLC AstraZeneca PLC
AZN
0.08 - - $ 96.9 B britainBritain
AVROBIO AVROBIO
AVRO
0.27 - 1083.1 % $ 745 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
-5.97 $ 2.91 -1.36 % $ 4.79 M israelIsrael
BioDelivery Sciences International BioDelivery Sciences International
BDSI
0.85 - -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
0.2 - 0.49 % $ 251 B cayman-islandsCayman-islands
Akero Therapeutics Akero Therapeutics
AKRO
-3.75 - - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-2.21 - - $ 867 M germanyGermany
bluebird bio bluebird bio
BLUE
-1.93 - - $ 546 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
-125 - -5.16 % $ 5.39 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
-0.34 $ 6.84 2.7 % $ 195 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
-5.73 $ 1.06 -3.64 % $ 12.9 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
-2.1 $ 2.95 -3.28 % $ 296 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
-2.46 - -3.03 % $ 260 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-0.72 - 3.16 % $ 1.9 M usaUSA